PDSB — PDS Biotechnology Balance Sheet
0.000.00%
- $45.57m
- $37.33m
Annual balance sheet for PDS Biotechnology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 28.8 | 65.2 | 73.8 | 56.6 | 41.7 |
| Prepaid Expenses | |||||
| Total Current Assets | 30.3 | 66.8 | 76.5 | 59.1 | 45.1 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.553 | 0.358 | 0.528 | 0.335 | 0.304 |
| Total Assets | 30.9 | 67.2 | 77 | 59.4 | 45.4 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.27 | 3.76 | 9.82 | 13.6 | 17.1 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 3.76 | 3.99 | 33 | 33.3 | 26.4 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 27.1 | 63.2 | 44 | 26.1 | 19 |
| Total Liabilities & Shareholders' Equity | 30.9 | 67.2 | 77 | 59.4 | 45.4 |
| Total Common Shares Outstanding |